Procurou por: Rosmarinic+acid

Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.

Código de Artigo: BOSSBS-2950R-A750

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção

Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.

Código de Artigo: BOSSBS-2950R-CY5

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção

Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.

Código de Artigo: BOSSBS-2950R-A488

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção

Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.

Código de Artigo: BOSSBS-2950R-CY3

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção

Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.

Código de Artigo: BOSSBS-2950R-A350

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção

Descrição: Converts cytosine to uracil or 5-methylcytosine to thymine by deaminating carbon number 4.

Código de Artigo: BOSSBS-2950R-FITC

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção

Descrição: THYMIN-1-YLACETIC ACID 1 * 25 g

Código de Artigo: APOSOR15418-25G

UOM: 1 * 25 g

Fornecedor: Apollo Scientific

Promoção

Descrição: THYMIN-1-YLACETIC ACID 1 * 100 g

Código de Artigo: APOSOR15418-100G

UOM: 1 * 100 g

Fornecedor: Apollo Scientific

Promoção

Descrição: TDG (THYMINE DNA GLYCOSYLASE) MAB 1 * 100 µl

Código de Artigo: CAYM32981-100

UOM: 1 * 100 µl

Fornecedor: Cayman Chemical

Promoção

Descrição: RECOMBINANT HUMAN THYMINE DNA GLYCOSYLAS 1 * 100 µG

Código de Artigo: ABCAAB134525-100

UOM: 1 * 100 µG

Fornecedor: Abcam

Promoção

Descrição: This molecular model can show how the bases (adenin, cytosin, guanin, thymin) are combined through triple and double hydrogen bonds.

Código de Artigo: SPIRMKO-ACGT-53

UOM: 1 * 1 unid.

Fornecedor: SPIRING ENTERPRISES

Promoção

Descrição: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

Código de Artigo: BOSSBS-8288R-CY7

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção

Descrição: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

Código de Artigo: BOSSBS-8288R-FITC

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção

Descrição: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterised by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

Código de Artigo: BOSSBS-8288R-A680

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção

Descrição: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

Código de Artigo: BOSSBS-8288R-A555

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção

Descrição: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

Código de Artigo: BOSSBS-8288R-HRP

UOM: 1 * 100 µl

Fornecedor: Bioss

Promoção